Immuno Oncology

Immuno Oncology

Immunotherapy Combination Confers Durable Benefit in Advanced Renal Cell Carcinoma

First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to new study results. 

SSTP1, a Host Defense Peptide, Exploits the Immunomodulatory IL6 Pathway to Induce Apoptosis in Cancer Cells

Researchers suggests that identification of the membrane targets for the promising anticancer HDPs might lead to the identification of new drugs for targeted therapy.

Frontiers in Immunology
Role of Immunotherapy in Localized Muscle Invasive Urothelial Cancer

Study investigators report results from clinical trials using single agent ICI, ICI/ICI and ICI/chemo combination therapies in the neoadjuvant setting for non-metastatic MIBC. 

Therapeutic Advances in Medical Oncology

Response Endpoints Deemed ‘Poor Surrogates’ for Overall Survival in Trials of Immune Checkpoint Inhibitors

Tumor response endpoints are “poor surrogate endpoints” for OS in trials of immune checkpoint inhibitors, according to research published in JCO Precision Oncology.

Cancer Therapy Advisor
Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers

The aim of this study is to systematically identify the roles of checkpoint HLA-G molecules across various types of cancer.

Frontiers in Immunology
Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects.

The ASCO Post
Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles
mRNA in Cancer Immunotherapy: Beyond a Source of Antigen

Many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. 

Molecular Cancer
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects.

OncoTargets and Therapy
Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology
The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

This review focuses on m6A-associated regulation, mechanisms, and functions in acquired chemoresistance, radioresistance, and resistance to immunotherapy in cancer.

Frontiers in Oncology
A Small-Molecule P2RX7 Activator Promotes Anti-Tumor Immune Responses and Sensitizes Lung Tumor to Immunotherapy

Only a subpopulation of NSCLC patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome.

Radiotherapy–Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?

This review assesses the important clinical questions that need to be addressed to successfully combine radiotherapy and immunotherapy treatments by rethinking approaches to...

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

Efforts to understand mechanisms of resistance and increase efficacy of immune checkpoint blockade in pancreatic cancer require the use of appropriate preclinical models in the laboratory.

Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma

Therapies targeting immune molecules have rapidly been adopted and advanced the treatment of hepatocellular carcinoma. 

Frontiers in Oncology
Immuno-oncology: Are TAM Receptors in Glioblastoma Friends or Foes?

In this study, investigators aim to cast a spotlight on the potential multidirectional effects of TAM receptors in glioblastoma and provide a better understanding for TAM receptor-related targeted

The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma

The aim of this review article is to characterize the profile of efficacy and safety of immuno-oncology-based monotherapies that failed to demonstrate significant benefit...

Targeting Hypoxia in the Tumor Microenvironment: A Potential Strategy to Improve Cancer Immunotherapy

In this review, the potential impact of hypoxia within the TME, in terms of key immune cell populations, and the contribution to immune suppression are discussed.

The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy

The role of the biochemical pathway of antigen presentation in cancer and how it can be modulated to enhance the efficacy of cancer immunotherapy is discussed.

PET Imaging Facilitates Antibody Screening for Synergistic Radioimmunotherapy With a 177Lu-Labeled αPD-L1 Antibody

The low response rate of immunotherapy, such as anti-PD-L1/PD-1 and anti-CTLA4, has limited its application to a wider population of cancer patients.

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

This review shows the latest research progress, the advantages, the disadvantages, and the application of immunocyte membrane-coated nanoparticles in cancer immunotherapy.

The Microbiome and Its Implications in Cancer Immunotherapy

This review mainly focuses on various microbes and their association with different types of cancer, responses to immunotherapeutic modulation...

Society for Immunotherapy of Cancer Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups.

Noninvasive Imaging of Cancer Immunotherapy

This study reviews recent developments in the field of noninvasive cancer imaging with a focus on immunotherapeutics and nuclear imaging technologies.

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Exciting data from recent clinical trials have renewed interest in the field of cancer immunotherapy due to the potential of CAR NK cells in the production of “off-the-shelf” anti-cancer...

Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarker.

The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies

This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated...

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

The B cell surface antigen CD19 is a target for treating malignancies, such as precursor acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Annals of Hematology
Immuno-oncology cell therapy branches out

Optimization of CAR-T cell technology and application other immune types such as NK cells are tackling the efficacy, cost logistical challenges therapies for cancer....

Biopharma Dealmakers
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Immuno-oncology and cell therapy, the frontier of cancer treatment, is a rapidly developing area that brings new opportunities to patients.

Contemporary Clinical Trials
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.

Conventional dose finding designs in oncology drug development target on the identification of maximum tolerated (MTD), with assumption that MTD has...

Journal of Biopharmaceutical Statistics
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology

The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment described...


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)